LMR Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

LMR Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-9,800	Closed	-$693K	–	1392
2025 Q1	$693K	Hold	9,800	–	–	0.01%	857
2024 Q4	$644K	Sell	9,800 -100,000	-91%	-$6.7M	0.01%	794
2024 Q3	$7.72M	Buy	+109,800	New	+$9.18M	0.06%	269
2023 Q3	–	Sell	-39,000	Closed	-$3.38M	–	946
2023 Q2	$3.38M	Buy	+39,000	New	+$3.67M	0.04%	291

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

LMR Partners's BMRN Position: Q2 2026 in Review

LMR Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 324,939 shares — an estimated $18.4M sold.

LMR Partners first reported a position in BMRN in Q3 2019 and held it in 19 quarters. The position peaked at $18.4M in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

LMR Partners reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
LMR Partners sold 324,939 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $18.4M.
LMR Partners first reported a position in BioMarin Pharmaceuticals in Q3 2019 and held it in 19 quarters.
LMR Partners's BioMarin Pharmaceuticals position peaked at $18.4M in Q1 2026.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.